March 12, 2020
Millions of Americans (mainly millennials) trapped in the gig-economy with insurmountable debts are soon going to experience further financial hardships as a result of a Covid-19 breakout across the country, grinding their local economies to a standstill.
With job losses expected as the gig-economy implodes, and many metro areas across the country are transforming into ghost towns, millennials will need to figure out new ways to make money, that is because they need to service their auto debt, credit cards, and student loans.
One such opportunity, at the moment, is to be a guinea pig for biotechnology companies developing coronavirus vaccines. Now, remember, you will be handsomely rewarded, but also, you’re going to save the human race for extinction.
As GreatGameIndia.com details, in a $2 billion race to find a vaccine various companies are infecting humans with Coronavirus for clinical trials. A medical research firm based in the U.K. is offering more than $4,500 to individuals willing to serve as guinea pigs and be injected with two strains of Coronavirus similar to COVID-19 in a bid to find a vaccine for the new deadly virus. In the U.S., another firm is seeking participants for a COVID-19 vaccine study, but the pay is not as high, nor as quick, nor as risky.
The offer comes from London-based company Hvivo, which is seeking 24 healthy individuals at a time to receive the weaker shots of Coronavirus before being administered vaccines in what the Times of London described as “a $2 billion race to find a vaccine” for COVID-19.
According to the New York Post, participants would make around $4,588 to participate in Hvivo’s “flu camp,” which entails a two-week quarantine where they must “eat a restricted diet and avoid human contact and exercise.”
“Volunteers are vital to the work we do at FluCamp. Thousands of people have already taken part in our ethically and regulatory approved clinical studies, with trials designed for those with and without asthma. These volunteers help us to achieve great steps forward in understanding the common cold and flu viruses, and how they can be treated,” FluCamp’s website read.
The firm is still awaiting approval from the U.K.’s Medicines and Healthcare products Regulatory Agency before trials can begin — but even if it gets clearance quickly, a cure is not expected until next winter, despite more than 20 firms participating in the race to find a shot to prevent the virus that has already taken nearly 4,000 lives globally.
In the U.S., another firm is seeking participants for a COVID-19 vaccine study, but the pay is not as high, nor as quick, nor as risky.
Business Insider reported that Seattle’s Kaiser Permanente Washington research clinic plans to enroll 45 healthy folks to participate in a 14-month trial to test three doses of a potential vaccine against the novel Coronavirus for safety.
However, in the Seattle study, participants would not be injected with the Coronavirus. The researchers are offering $100 per visit for volunteers to show up in person 11 times, offering a total payout of $1,100 for those willing to serve as guinea pigs to test out the safety of what could be a life-saving vaccine.
This article was posted: Thursday, March 12, 2020 at 5:46 am